Trade First Wave BioPharma, Inc. - FWBI CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1420 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.909 |
| Open | 2.909 |
| 1-Year Change | 6.1% |
| Day's Range | 2.909 - 3.339 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 3.1090 | 0.2000 | 6.88% | 2.9090 | 3.3390 | 2.8990 |
| Apr 22, 2024 | 2.9090 | 0.3100 | 11.93% | 2.5990 | 3.0390 | 2.3990 |
| Apr 19, 2024 | 2.5990 | -0.2100 | -7.48% | 2.8090 | 2.9490 | 2.3690 |
| Apr 18, 2024 | 2.8090 | -0.0700 | -2.43% | 2.8790 | 2.8990 | 2.6290 |
| Apr 17, 2024 | 2.7890 | -0.1100 | -3.79% | 2.8990 | 2.9590 | 2.7490 |
| Apr 16, 2024 | 2.9790 | -0.1200 | -3.87% | 3.0990 | 3.2390 | 2.9390 |
| Apr 15, 2024 | 3.1790 | -0.1200 | -3.64% | 3.2990 | 3.4190 | 3.1090 |
| Apr 12, 2024 | 3.2990 | -0.1500 | -4.35% | 3.4490 | 3.4490 | 3.2190 |
| Apr 11, 2024 | 3.3390 | -0.0600 | -1.77% | 3.3990 | 3.5290 | 3.2490 |
| Apr 10, 2024 | 3.4090 | -0.1900 | -5.28% | 3.5990 | 3.5990 | 3.3090 |
| Apr 9, 2024 | 3.5090 | -0.2200 | -5.90% | 3.7290 | 3.7290 | 3.4990 |
| Apr 8, 2024 | 3.7490 | -0.2000 | -5.06% | 3.9490 | 3.9490 | 3.6990 |
| Apr 5, 2024 | 3.9490 | -0.0200 | -0.50% | 3.9690 | 4.0190 | 3.8490 |
| Apr 4, 2024 | 3.9790 | 0.0300 | 0.76% | 3.9490 | 4.0590 | 3.9290 |
| Apr 3, 2024 | 3.9490 | -0.2300 | -5.50% | 4.1790 | 4.3590 | 3.9090 |
| Apr 2, 2024 | 3.8990 | -0.1800 | -4.41% | 4.0790 | 4.1390 | 3.8690 |
| Apr 1, 2024 | 4.1590 | -0.3800 | -8.37% | 4.5390 | 4.5390 | 3.9990 |
| Mar 28, 2024 | 4.3890 | 0.4900 | 12.57% | 3.8990 | 4.5190 | 3.8090 |
| Mar 27, 2024 | 3.9090 | -0.0900 | -2.25% | 3.9990 | 4.0590 | 3.8090 |
| Mar 26, 2024 | 3.9590 | -0.0400 | -1.00% | 3.9990 | 4.0690 | 3.8990 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
First Wave BioPharma, Inc. Company profile
About First Wave BioPharma Inc
First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com